Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.

BMC Cancer · 2022 · PMC9535983 · PMID 36203123

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

showed a trendP = 0.053so close (0.05 < p ≤ 0.1)

Patients treated with combination therapy showed a trend toward a longer PFS if an irAE was documented [9.7 months vs. 7.1 months, (HR, 0.50; 95% CI, 0.25–1.02; P = 0.053); Fig. 1 c].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.